158 related articles for article (PubMed ID: 14682297)
1. [Effect of imidazoline receptor agonist moxonidine on the state of microcirculation and renal function in patients with hypertension and diabetes mellitus type 2].
Trusov VV; Aksenov KV
Kardiologiia; 2003; 43(9):44-8. PubMed ID: 14682297
[No Abstract] [Full Text] [Related]
2. Microvascular benefits of hypertension and glucose control in type 2 diabetes.
van Rensburg BW
Cardiovasc J Afr; 2008; 19(4):179-80. PubMed ID: 18776957
[No Abstract] [Full Text] [Related]
3. [The kidney as a target organ in diabetic patients with arterial hypertension].
Viberti G
Drugs; 2003; 63 Spec No 1():31-7. PubMed ID: 12708880
[TBL] [Abstract][Full Text] [Related]
4. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
Lazebnik LB; Malichenko SB; Serebrov AN
Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
[No Abstract] [Full Text] [Related]
5. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches.
Weir MR; Bakris GL
Postgrad Med; 1992 Feb; 91(3):87-91, 94-5. PubMed ID: 1741369
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
7. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.
Parving HH; Andersen AR; Smidt UM; Svendsen PA
Lancet; 1983 May; 1(8335):1175-9. PubMed ID: 6133986
[TBL] [Abstract][Full Text] [Related]
8. Achieved vs initial blood pressure in predicting renal outcomes.
Onuigbo MA
Arch Intern Med; 2004 Jan; 164(2):223; author reply 223-4. PubMed ID: 14744850
[No Abstract] [Full Text] [Related]
9. [The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
Dtsch Med Wochenschr; 1998 Aug; 123(33 Suppl):1-4. PubMed ID: 9739350
[No Abstract] [Full Text] [Related]
10. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
11. Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild-to-moderate hypertension.
Martina B; Surber C; Jakobi C; Sponagel L; Gasser P
Angiology; 1998 Nov; 49(11):897-901. PubMed ID: 9822045
[TBL] [Abstract][Full Text] [Related]
12. [Effect of eprosartan on microcirculation and blood rheology in patients with hypertensive disease].
Markova LI; Koren'kov VV; Shakhova NI; Radzevich AE
Kardiologiia; 2004; 44(2):27-9. PubMed ID: 15029132
[TBL] [Abstract][Full Text] [Related]
13. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
[TBL] [Abstract][Full Text] [Related]
14. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
[TBL] [Abstract][Full Text] [Related]
15. [Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
Minushkina LO
Kardiologiia; 2011; 51(4):74-8. PubMed ID: 21623724
[TBL] [Abstract][Full Text] [Related]
16. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas.
Mogensen CE
Diabetologia; 1999 Mar; 42(3):263-85. PubMed ID: 10096778
[No Abstract] [Full Text] [Related]
17. [Clinical assessment of prolonged therapy of patients with hypertension and diabetes with imidazoline receptor agonist moxonidine].
Trusov VV; Aksenov KV; Filimonov MA
Kardiologiia; 2002; 42(2):50-3. PubMed ID: 12494208
[No Abstract] [Full Text] [Related]
18. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
Chantrel F; Bouiller M; Kolb I; Hannedouche T
Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
[TBL] [Abstract][Full Text] [Related]
19. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
[TBL] [Abstract][Full Text] [Related]
20. Moxonidine: a review of its use in essential hypertension.
Fenton C; Keating GM; Lyseng-Williamson KA
Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
